ReviewCancers2020
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06416436 (Immunotherapy in Combination With Ablative Radiosurgery to Ultra-high DoSes), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunotherapy in Combination With Ablative Radiosurgery to Ultra-high DoSes (ICARUS): A Phase I Dose-escalation Radiosurgery Study in Metastatic Cancers
Who cites it
31 citing papers in PubMed, 68 citations in OpenAlex.
- Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Integrative radiomics and habitat imaging models for predicting PD-L1 expression in non-small cell lung cancer.Frontiers in oncology · 2026Article
- Advances in immunoPET/SPECT imaging: The role of Fab and F(ab')Acta pharmaceutica Sinica. B · 2025Review
- Article
- PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC).Discover oncology · 2025Review
- Deep learning-based multimodal approach for non-invasive prediction and prognostic analysis of immune and angiogenic biomarkers in extrahepatic cholangiocarcinoma.Frontiers in immunology · 2025Article
- Biomarkers for Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- PET imaging of PD-L1 with a small molecule radiotracer.European journal of nuclear medicine and molecular imaging · 2024Article
- Predictions of PD-L1 Expression Based on CT Imaging Features in Lung Squamous Cell Carcinoma.Journal of the Korean Society of Radiology · 2024Article
- Review
- Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.European journal of nuclear medicine and molecular imaging · 2024Article
- Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.Frontiers in medicine · 2024Review
- The Expression of Programmed Death-Ligand 1 on Immune Cells Is Related to a Better Prognosis in Biliary Tract Cancer.Gut and liver · 2023Article
- Non-invasive PD-L1 quantification using [Journal for immunotherapy of cancer · 2023Article
- Article
- Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- PD-L1 testing by immunohistochemistry in immuno-oncology.Biomolecules & biomedicine · 2023Review
- Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.International journal of nanomedicine · 2023Article
- Evaluation of a Radiolabeled Macrocyclic Peptide as Potential PET Imaging Probe for PD-L1.ChemMedChem · 2022Article
- PET imaging of an optimized anti-PD-L1 probeEJNMMI research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Therapeutics targeting programmed death ligand 1 (PD-L1) protein and its receptor PD-1 are now dominant players in restoring anti-tumor immune responses. PD-L1 detection by immunohistochemistry (IHC) is emerging as a reproducible biomarker for guiding patient stratification for those therapies in some cancers. However, PD-L1 expression in the tumor microenvironment is highly complex. It is upregulated by aberrant genetic alterations, and is highly regulated at the transcriptional, posttranscriptional, and protein levels. Thus, PD-L1 IHC is inadequate to fully understand the relevance of PD-L1 levels in the whole body and their dynamics to improve therapeutic outcomes. Imaging technologies could potentially assist in meeting that need. Early clinical investigations show promising results in quantifying PD-L1 expression in the whole body by positron emission tomography (PET). Within this context, this review summarizes advancements in regulation of PD-L1 expression and imaging agents, and in PD-L1 PET for drug development, and discusses opportunities and challenges presented by these innovations for guiding immune checkpoint therapy (ICT).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.